ghdx kimberly j popovits insider trades for genomic health inc bulletin investor alert tokyo markets close in currencies europe markets london markets expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close genomic health inc nasdaq ghdx go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus genomic health inc after hours  quotes are delayed by  min jul    pm ghdx quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite todays close     change   day low day high    week low  week high   insider activity individual kimberly j popovits ms kimberly j popovits is chairman president  chief executive officer at genomic health inc and president at the coalition for st century medicine she is on the board of directors at american clinical laboratory association california biomedical innovation alliance and personalized medicine coalition ms popovits was previously employed as independent director by zs pharma inc vice chairman by nuvelo inc senior vice presidentmarketing  sales by genentech inc and a manageramerican critical care division by american hospital supply corp she also served on the board at the bay area bioscience association she received her undergraduate degree from michigan state university transactions date shares transaction value     disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      gift at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      gift at  per share      gift at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      award at  per share      gift at  per share      gift at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      gift at  per share      gift at  per share      award at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      gift at  per share      gift at  per share      gift at  per share      gift at  per share      derivativenonderivative trans at  per share      award at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      gift at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      gift at  per share      gift at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      award at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      gift at  per share      gift at  per share      gift at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      award at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      gift at  per share      gift at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives ms kimberly j popovits chairman president  chief executive officer mr g bradley cole coo cfo  principal accounting officer mr michael vedda chief information officer dr phillip g febbo chief medical officer dr steven shak chief scientific officer ms janna sipes vp chief compliance  privacy officer dr frederic g pla chief business  product development officer dr jon cassel senior vice presidentoperations mr james j vaughn chief commercial officer mr lewis j stuart vice presidentsales  marketing ms laura leber chief communications officer ms kim mceachron chief people officer mr jason w radford secretary  chief legal officer mr jonathan truelove vice president  general counsel mr geoffrey m parker independent director dr fred e cohen independent director mr julian charles baker lead independent director dr henry j fuchs independent director dr felix james baker independent director ms ginger l graham independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo open marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest palphabet earnings keep google investors in dark pthe scientifically proven reason you should stop feeling guilty about ordering takeout pis this why united tsa clashed on twitter over comic books on planes pfed to stick to plans for rate hike balancesheet selloff this year pmls says no to promotionandrelegation regime — and  billion to boot pbitcoin platform scores key greenlight from wall street regulator palphabet falls after earnings beat live blog recap pis kushners statement a turning point for trump team pyear treasury yield snaps sixday streak of declines pcompanies do better when ceo pay dwarfs average worker study finds panadarko shares down  after company posts widerthanexpected loss palphabet falls after earnings beat live blog ptrump pushes gop for affordable care act repeal pus will go singlepayer route on health care jimmy carter pnasdaq closes at record as tech stocks shake off broader weakness pwatch out for these surprise charges at the er popinion journal congresss russia sanctions calculus popinion journal robert mueller’s power play popinion journal joseph rago popinion journal americans abroad beware loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice    meet our executive team and board of directors genomic health inc i agree genomic health does not give treatment for cancer or advise patients on their treatment plans anyone in doubt about their own health or cancer should seek medical advice from a qualified healthcare professional placeholder menu who we are what we do oncotype iq products who we help join our team investors newsroom resources portal login who we are back overview our mission company timeline  milestones leadership contact us what we do back overview clinical leadership world class commercial channel oncotype iq products back overview oncotype dx oncotype dx for breast cancer oncotype dx for prostate cancer oncotype dx for colon cancer oncotype seq liquid select our product pipeline who we help back overview join our team back overview us benefits international benefits united states  english back united states  english deutschland  deutsch france  français italia  italiano japan  japanese united kingdom  english genomic health is the worlds leading provider of genomicbased diagnostic tests that address both the overtreatment and optimal treatment of earlystage cancer one of the greatest issues in healthcare today learn more overview our mission company timeline  milestones leadership contact us genomic health and oncotype iq – delivering precision medicine watch how genomic health continues to transform cancer care around the world watch video it is our mission to transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services for patients learn more overview clinical leadership world class commercial channel individual molecular fingerprint of tumors kim popovits discusses devising personalized medicine in the treatment of breast cancer and colon cancer watch video our portfolio of tests is aimed at delivering genomic intelligence that optimizes treatment decisions throughout the cancer patient journey learn more overview oncotype dx oncotype dx for breast cancer oncotype dx for prostate cancer oncotype dx for colon cancer oncotype seq liquid select our product pipeline not all breast cancer is the same get your oncotype dx score hear how breast cancer survivors personalized their cancer treatment with oncotype dx watch video genomic health is driven by the commitment to improving the lives of cancer patients learn more overview your prostate your decision interview with dan dan was diagnosed with earlystage prostate cancer watch dan talk about his experience with the oncotype dx prostate cancer test watch video inspired by the life changing work that we do be a part of the worlds leading provider of genomic cancer diagnostic tests learn more overview us benefits international benefits the genomic health brand and company mission watch ceo kim popovits and others discuss the motivation inspiration and rewards of working at genomic health as well as the company’s vision for the future watch video toggle search✖ leadership experienced leadership committed to delivering results meet our executive team and board of directors genomic health inc genomic healths team has extensive experience in a variety of cuttingedge technical fields including the molecular diagnostics information technology biotechnology pharmaceutical and genomic industries team members have demonstrated continued success in starting businesses researching and developing novel drugs launching products building successful organizations and delivering value to shareholders   filter by management team vice presidents board of directors kimberly popovits chairman of the board chief executive officer  president g bradley cole chief operating officer  chief financial officer steven shak md cofounder chief scientific officer frederic pla phd chief business  product development officer jim vaughn rph chief commercial officer phil febbo md chief medical officer laura leber chief communications officer kim mceachron chief people officer jason radford chief legal officer  secretary ellen beasley phd senior vice president products and services rd jon cassel phd senior vice president operations mike vedda senior vice president information technology chief information officer julian baker felix baker phd fred cohen md dphil henry j fuchs md ginger l graham geoffrey m parker kimberly popovits julian baker managing partner lead independent director baker brothers investments julian baker has served as a director of genomic health since january  mr baker is a managing partner of baker brothers investments which he and his brother felix baker phd founded in  mr baker’s firm manages a family of longterm investment funds for major university endowments and foundations which are focused on publicly traded life sciences companies mr baker’s career as a fund manager began in  when he cofounded a biotechnology investing partnership with the tisch family now known as bakertisch investments previously mr baker was employed from  to  by the private equity investment arm of credit suisse first boston corporation he is also a director of incyte corporation neurogen corporation theravance inc and trimeris inc mr baker holds a bachelor of arts in social studies from harvard university felix baker phd managing partner baker brothers investments felix j baker phd has served as a director of genomic health since  felix j baker is a managing partner of baker brothers investments which he and his brother company director julian c baker founded in  dr baker’s firm manages a family of longterm investment funds for major university endowments and foundations which are focused on publicly traded life sciences companies dr baker’s career as a fundmanager began in  when he cofounded a biotechnology investing partnership with the tisch family dr baker holds a bachelor of science and a phd in immunology from stanford university where he also completed two years of medical school dr baker currently serves as a director of seattle genetics inc and synageva biopharma corp both of which are publiclytraded biotechnology companies fred cohen md dphil senior advisor tpg fred e cohen md dphil has served as a director of genomic health since april  dr cohen is a senior advisor to tpg where he served as a partner and founder of tpg biotechnology from  to  dr cohen was a professor of medicine and pharmacology at the university of california san francisco where he taught from  to  dr cohen serves as a director of biocryst pharmaceuticals inc caredx inc fiveprime therapeutics inc quintiles transnational holdings inc roka bioscience inc tandem diabetes care inc veracyte inc and other privately held companies dr cohen holds a bachelor of science degree in molecular biophysics and biochemistry from yale university a dphil in molecular biophysics from oxford university and an md degree from stanford university henry j fuchs md executive vice president and chief medical officer biomarin pharmaceutical inc henry j fuchs md has served as a director of genomic health since september  dr fuchs is the executive vice president and chief medical officer of biomarin pharmaceutical inc a biopharmaceutical company from september  to december  dr fuchs was executive vice president and chief medical officer of onyx pharmaceuticals inc a biopharmaceutical company from october  until june  dr fuchs served in multiple roles of increasing responsibility at ardea biosciences inc a biotechnology company first as vice president clinical affairs then as president and chief operating officer and finally as president and chief executive officer from  to  dr fuchs held various positions at genentech inc a biotechnology company dr fuchs serves as a director of mirati therapeutics inc and served as a director of ardea biosciences inc from november  to june  dr fuchs received a bachelor of arts degree in biochemical sciences from harvard university and an md degree from george washington university ginger l graham former president and ceo amylin pharmaceuticals ginger l graham has served as a director of genomic health since  ms graham is a member of the harvard business school health industry alumni advisory board the university of arkansas chancellor’s campaign steering committee and the advisory board for the biofrontiers institute at the university of colorado she is also a director of walgreen co the proteus digital health pharmaceutical division surefire medical elcelyx therapeutics and the circle of life hospice foundation ms graham serves on the advisory board for the kellogg center for executive women and cochairs the scientific council of the university of colorado’s center for women’s health research geoffrey m parker chief financial officer and senior vice president tricida inc geoffrey m parker has served as a director of genomic health since june  he is currently chief financial officer and senior vice president at tricida inc and a member of the board of directors at chemocentryx inc perrigo company plc and sunesis pharmaceuticals inc prior to that mr parker was the executive vice president of anacor pharmaceuticals inc from may  to may  additionally he was the chief financial officer of anacor pharmaceuticals inc from september  to may  mr parker served as the vice president managing director and partner at the global investment banking and securities firm goldman sachs  co leading their west coast healthcare investment banking practice from april  to april  from  to  mr parker was vice president at feibusch  co a venture capital firm in larkspur california mr parker received an ab from dartmouth college in engineering sciences and economics and an mba from the stanford graduate school of business kimberly popovits chairman of the board chief executive officer  president committed to changing the paradigm of cancer care kim popovits has led genomic health in revolutionizing the treatment of cancer through genomicbased diagnostic tests for breast colon and prostate cancers that personalize and optimize treatment decisions kim has served as genomic healths chairman of the board since  and chief executive officer and president since  she was president and chief operating officer since joining the company in  prior to joining genomic health kim served as senior vice president marketing and sales at the biotechnology company genentech inc during her  years at genentech kim led the successful commercialization of  new therapies including herceptin® the revolutionary targeted treatment that changed the way doctors treat a particularly aggressive form of breast cancer kim currently serves on the boards of the california life sciences association clsa the personalized medicine coalition pmc the american clinical laboratory association acla and myokardia kim is also the president of the coalition for st century medicine kims contributions to the science and commercialization of the biotechnology industry have been acknowledged by multiple organizations including being named most admired ceo in  and one of the forever influential women in the bay area from by the san francisco business times she was also named woman of the year by women health care executives in  received the ferolyn powell leadership award from medtechwomen in  and received the salute to excellence award from the american liver foundation in  kim holds a bachelor of arts degree in business from michigan state university frederick baehner md vice president pathology rolando brawer vice president corporate development calvin chao vice president global medical affairs irene chen vice president clinical lab operations emily faucette vice president corporate communications  investor relations michael hicks vice president us urology business brian hogan vice president finance annie inglis vice president global commercial operations mike lelivelt vice president product lifecycle management juliette plunfavreau vice president international market access reimbursement  government affairs janna sipes esq vice president chief compliance officer  privacy officer lewis stuart vice president sales  marketing us breastcolon jonathan truelove vice president general counsel international jim whitmore vice president biostatistics  data management who we are our mission company timeline  milestones leadership contact us follow us connect with us and get the latest news on genomics and transforming cancer care learn more the genomic health brand and company mission watch ceo kim popovits and others discuss the motivation inspiration and rewards of working at genomic health as well as the companys vision for the future watch video the genomic health brand and company mission watch ceo kim popovits and others discuss the motivation inspiration and rewards of working at genomic health as well as the companys vision for the future watch video the genomic health brand and company mission watch ceo kim popovits and others discuss the motivation inspiration and rewards of working at genomic health as well as the companys vision for the future watch video follow us connect with us and get the latest news on genomics and transforming cancer care learn more follow us connect with us and get the latest news on genomics and transforming cancer care learn more who we are our mission timeline  milestones leadership contact us what we do clinical leadership commercial channel who we help join our team careers us benefits international benefits oncotype iq products oncotype dx for breast cancer for prostate cancer for colon cancer oncotype seq our product pipeline newsroom press releases media resources social hub in the news investors resources videos patient resources publications  guidelines abstracts grants  contributions glossary licenses  accreditations privacy policy terms  conditions licenses  accreditations privacy policy terms  conditions   genomic health all rights reserved   genomic health all rights reserved in the us and certain other jurisdictions genomic health oncotype dx oncotype iq recurrence score and oncotype seq are registered trademarks and genomic prostate score liquid select and arv nucleus detect are pending registered trademarks of genomic health inc   genomic health all rights reserved in the us and certain other jurisdictions genomic health oncotype dx oncotype iq recurrence score and oncotype seq are registered trademarks and genomic prostate score liquid select and arv nucleus detect are pending registered trademarks of genomic health inc kimberly j popovits  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in kimberly j popovits chairman of the board president and chief executive officer at genomic health inc view full profile are you kimberly j popovits claim your profile   sign up for equilar atlas and view kimberly j popovitss full profile with equilar atlas you can identify corporate executives in kimberly j popovitss network and community follow changes in kimberly j popovitss employment and moneyinmotion connect with kimberly j popovits through your network of contacts kimberly j popovitss executive work history current chairman of the board president and chief executive officer genomic health inc board member myokardia inc past to view kimberly j popovitss complete executive work history sign up now age      kimberly j popovitss biography kimberly j popovits has served as our president and chief executive officer since january  and as chairman of the board since march   prior to that ms popovits served as president and chief operating officer from february  to january  from november  to february  ms popovits served in various roles at genentech inc a biotechnology company most recently serving as senior vice president marketing and sales from february  to february  and as vice president sales from october  to february  prior to joining genentech ms popovits served as division manager southeast region for american cr  read more kimberly j popovits has served as our president and chief executive officer since january  and as chairman of the board since march   prior to that ms popovits served as president and chief operating officer from february  to january  from november  to february  ms popovits served in various roles at genentech inc a biotechnology company most recently serving as senior vice president marketing and sales from february  to february  and as vice president sales from october  to february  prior to joining genentech ms popovits served as division manager southeast region for american critical care a division of american hospital supply a supplier of healthcare products to hospitals ms popovits serves as a director of myokardia inc a precision medicine company ms popovits holds a ba in business from michigan state university source genomic health inc on    sign up for equilar atlas and view kimberly j popovitss full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like kimberly j popovits more specifically youll be able to identify corporate executives in kimberly j popovitss network and community follow changes in kimberly j popovitss employment and moneyinmotion connect with kimberly j popovits through your network of conections view full profile   search for over  executive profiles bio example kimberly j popovits kimberly j popovitss connections  sign up now to view kimberly j popovitss  connections » barry l zubrow board member canadian imperial bank of commerce mary b cranston board member visa inc geoffrey m parker board member chemocentryx inc paul j hastings chairman of the board chief executive officer and president oncomed pharmaceuticals inc kevin p starr board member alnylam pharmaceuticals inc henry j fuchs president worldwide research and development biomarin pharmaceutical inc steven shak chief scientific officer genomic health inc srinivas akkaraju board member seattle genetics inc mark l perry board member nvidia corporation g bradley cole chief operating officer chief financial officer and secretary genomic health inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith elon r musk ceo and chairman tesla claiborne p deming chairman of the board murphy oil corporation daniel a dematteo executive chairman gamestop corp × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   compensation information for kimberly j popovits  president and chief executive officer of genomic health inc  salarycom enterprise small business personal contact us log in salaries jobs education advice kimberly j popovits executive compensation as president and chief executive officer at genomic health inc kimberly j popovits made  in total compensation of this total  was received as a salary  was received as a bonus  was received in stock options  was awarded as stock and  came from other types of compensation this information is according to proxy statements filed for the  fiscal year enter an executive or company name new search go the chart on this page features a breakdown of the total annual pay for kimberly j popovits  president and chief executive officer at genomic health inc as reported in their proxy statements total cash compensation information is comprised of yearly base pay and bonuses genomic health inc income statements for executive base pay and bonus are filed yearly with the sec in the edgar filing system genomic health inc annual reports of executive compensation and pay are most commonly found in the def a documents total equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year other compensation covers all compensationlike awards that dont fit in any of these other standard categories numbers reported do not include change in pension value and nonqualified deferred compensation earnings other executives at this company g bradley cole steven shak md james vaughn frederic pla phd kimberly j popovits base pay bonus  incentive comp total cash compensation stock award value option award value total equity total other total compensation browse executives by first name a b c d e f g h i j k l m n o p q r s t u v w x y z browse companies by company name a b c d e f g h i j k l m n o p q r s t u v w x y z  this report is not for commercial use thorough reviews have been conducted to assure this data accurately reflects disclosures however for a complete and definitive understanding of the pay practices of any company users should refer directly to the actual complete proxy statement use of data  disclaimer the information shown here is a reporting of information included in the companys proxy statement the proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information for those interested in conducting a detailed compensation analysis we recommend that you review the entire proxy statement you may retrieve the full proxy statement by going to the securities and exchange commission sec website at wwwsecgov and entering the companys name and then looking in the first column for an entry of form def a or any similar code you may also find the annual proxy statement by going directly to the companys website what is a proxy statement a proxy statement or proxy is a form that every publicly traded us company is required to file with the us securities  exchange commission sec within  days after the end of its fiscal year the proxy must be sent to every shareholder in advance of the companys annual shareholders meeting all proxy statements are public filings made available to the general public by the sec the proxy statements main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting including decisions such as electing directors ratifying the selection of auditors and other shareholderrelated decisions including shareholderinitiated initiatives also proxies must disclose specific detailed information regarding the pay practices for certain executives       privacy policy terms of use about us contact us  salarycom all rights reserved us salaries canadian salaries purchase a salary report salaries by category salaries by income salaries by industry popular salaries negotiation tips benefits calculator search job openings job openings by state job openings by category education by career education by level education by major cost of living calculator zs pharma appoints kimberly popovits to board of directors  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street zs pharma appoints kimberly popovits to board of directors globenewswire may    pm edt redwood city calif may   globe newswire  zs pharma nasdaqzsph a biopharmaceutical company developing novel treatments for kidney cardiovascular liver and metabolic disorders today announced that kimberly j popovits chairman of the board chief executive officer and president of genomic health has been appointed to the zs pharma board of directors ms popovits brings significant leadership operations and commercial experience to zs pharma as the company prepares for the potential approval of zs sodium zirconium cyclosilicate we are extremely honored to have kim join our board of directors – she is a proven executive who has been successful starting new businesses launching and commercializing innovative products building successful organizations and delivering value to shareholders said robert alexander phd chief executive officer of zs pharma kim brings considerable experience to the zs pharma board of directors as the company prepares for regulatory approvals product launch and brand building for zs her seasoned judgment will be invaluable to our team as we enter the next critical phase of growth ms popovits added my commitment to developing emerging therapies or technologies that advance the practice of medicine and ultimately make patients lives better makes joining the zs pharma board a natural fit i look forward to working with existing board members and the zs pharma management team to support the companys vision of developing unique drugs to treat renal cardiovascular liver and metabolic diseases ms popovits current chairman of the board chief executive officer and president of genomic health has more than three decades of experience in the life sciences industry having held various commercialization and leadership roles in the healthcare industry prior to becoming the ceo of genomic health in  ms popovits was the senior vice president of marketing and sales at genentech during her  years at genentech she led the successful commercialization of  new therapies including herceptin® the revolutionary targeted treatment that changed the way doctors treat an aggressive form of breast cancer before joining genentech ms popovits was a division manager for american critical care a division of american hospital supply corporation if you liked this article you might like astrazeneca gets complete response letter from fda on hyperkalaemia treatment astrazeneca said friday that it had received a second complete response letter from the us fda regarding its hyperkalaemia treatment putting the drugs approval process in the united states doubt martin baccardax mar    am edt  speculative biotech stocks for  cempra and relypsa are two highrisk highreward smallcaps worth considering bret jensen dec    am est the nominees for best biopharma ceo of  are one of these biopharma executives or the grouped nominees will win the swanson trophy named in honor of robert swanson genentechs founding ceo here are the best biopharma ceos adam feuerstein dec    am est why relypsa is a new best idea it is hard to see the biotech firm not becoming a takeover target bret jensen dec    am est trending walmart in focus amid horrific human trafficking incident in texas that causes nine deaths earnings are back with a vengeance cramers mad money recap monday   stocks to give as gifts  things tesla doesnt want to admit as snap continues to stumble should it consider selling itself advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers zs pharma appoints kimberly popovits to board of directors employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       zs pharma zsph appoints kimberly popovits to board of directors tweet   am redwood city calif may   globe newswire  zs pharma nasdaqzsph a biopharmaceutical company developing novel treatments for kidney cardiovascular liver and metabolic disorders today announced that kimberly j popovits chairman of the board chief executive officer and president of genomic health has been appointed to the zs pharma board of directors ms popovits brings significant leadership operations and commercial experience to zs pharma as the company prepares for the potential approval of zs sodium zirconium cyclosilicate we are extremely honored to have kim join our board of directors – she is a proven executive who has been successful starting new businesses launching and commercializing innovative products building successful organizations and delivering value to shareholders said robert alexander phd chief executive officer of zs pharma kim brings considerable experience to the zs pharma board of directors as the company prepares for regulatory approvals product launch and brand building for zs her seasoned judgment will be invaluable to our team as we enter the next critical phase of growth ms popovits added my commitment to developing emerging therapies or technologies that advance the practice of medicine and ultimately make patients lives better makes joining the zs pharma board a natural fit i look forward to working with existing board members and the zs pharma management team to support the companys vision of developing unique drugs to treat renal cardiovascular liver and metabolic diseases ms popovits current chairman of the board chief executive officer and president of genomic health has more than three decades of experience in the life sciences industry having held various commercialization and leadership roles in the healthcare industry prior to becoming the ceo of genomic health in  ms popovits was the senior vice president of marketing and sales at genentech during her  years at genentech she led the successful commercialization of  new therapies including herceptin® the revolutionary targeted treatment that changed the way doctors treat an aggressive form of breast cancer before joining genentech ms popovits was a division manager for american critical care a division of american hospital supply corporation kim currently serves on the boards of clsa northern californias life science association and the american clinical laboratory association ms popovits is the president of the coalition for st century medicine whose mission is to improve the quality of healthcare by encouraging research development and commercialization of innovative diagnostic technologies that will personalize patient care improve patient outcomes and reduce healthcare costs ms popovits is an advisor to the healthcare businesswomens association she was named woman of the year in  by the women health care executives and has been recognized annually as one of the most influential women in the bay area by the san francisco business times since  in  the san francisco business times named kim one of the bay areas most admired ceos ms popovits holds a bachelor of arts degree in business from michigan state university about zs pharma zs pharma is a publicly traded nasdaqzsph biopharmaceutical company with offices in redwood city california and coppell texas zs pharmas lead therapeutic candidate zs sodium zirconium cyclosilicate is an investigational treatment for hyperkalemia that is being evaluated in latestage clinical trials to demonstrate its ability to safely and effectively remove excess potassium from the blood and maintain normal potassium levels zs pharma is also pursuing the discovery of additional drug candidates that utilize its novel selective iontrap technology for the treatment of kidney and liver diseases additional information about zs pharma is available at wwwzspharmacom forwardlooking statements zs pharma cautions you that this press release contains forwardlooking statements that involve risks and uncertainties we make such forwardlooking statements pursuant to the safe harbor provisions of the private securities litigation reform act of  and other federal securities laws any statements contained herein that are not statements of historical facts may be deemed to be forwardlooking statements in some cases you can identify forwardlooking statements by terminology such as aim anticipate assume believe contemplate continue could due estimate expect goal intend may objective plan predict potential positioned seek should target will would and other similar expressions that are predictions of or indicate future events and future trends or the negative of these terms or other comparable terminology these forwardlooking statements include but are not limited to statements about our expectations regarding the timing of submitting an nda to the fda and maa to the ema and the likelihood of regulatory approval of zs our expectations regarding our ability to successfully commercialize zs if approved estimates of our expenses future revenue capital requirements and needs for additional financing our ability to produce zs in commercial quantities in higher capacity reactors the initiation timing progress and results of future nonclinical studies clinical trials and research and development programs and our financial performance any forward looking statements in this press release are based on managements current expectations estimates forecasts and projections about our business and the industry in which we operate and managements beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks uncertainties and other factors that are in some cases beyond our control as a result any or all of our forwardlooking statements in this press release may turn out to be inaccurate factors that may cause actual results to differ materially from these expectations include among other things those listed under the heading risk factors in our registration statement on form s filed with the securities and exchange commission march   file no  which is available on the secs website at httpwwwsecgov all forwardlooking statements are qualified in their entirety by this cautionary statement and speak only as of the date of this press release except as required by law we assume no obligation to update or revise these forwardlooking statements for any reason even if new information becomes available in the future you should however review the factors and risks described in the reports we will file from time to time with the sec after the date of this press release contact zs pharma contacts adam tomasi investors zs pharma  atomasizspharmacom denise powell media red house consulting  deniseredhousecommscom help employers find you check out all the jobs and post your resume read at biospacecom related news zs pharma zsph announces publications in peerreviewed medical journals prescription for glaxosmithkline gsk a new leader zs pharma zsph announces upsizing and pricing of  million public offering of common stock acucela founder regains top spot at company after shareholder’s meeting zs pharma zsph announces proposed public offering of common stock rebellious sanofi sanpa investors made a mark at agm on ceo pay zs pharma zsph reports first quarter  financial results and provides zs program update as hampton takes over as chairman at glaxosmithkline gsk ceo witty needs to deliver or step aside zs pharma zsph reports fourth quarter and yearend  financial results and provides zs program update outgoing ariad aria ceo has no regrets and will work harder than ever until a successor is named please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • zs pharma   • biotechpharma  personnel                 page not found stay connected latest posts in rss businessentertainmentfeatured press releasefinancehealthlifestylenationnon firstpageoriginalreviewshoppingsportsstockstravel latest comments in rss  empowerednews world news summary helping you stay informed oops there was a  error page not found unfortunately the page you were looking for could not be found possibly you have done a typo error in the address or the page might have been removed from this website news categories business  stocks  entertainment  featured press release  finance  health  lifestyle  nation  non firstpage  original  review  shopping  sports  travel  photo gallery log in kimberly popovits  genomic health  inc  zoominfocom